Friday, 8th May Asia-Pacific Vaccine and Immunotherapy Congress 2026

• Harnessing Immunity to Prevent Ventilator-Associated Pneumonia Caused by Acinetobacter baumannii - Stephen Baker
• Engineering circular RNAs as effective vaccines and therapeutics - Yue Wan
• Adjuvant advantage in a longitudinal randomized control trial of alternating enhanced influenza vaccines in older adults - Sophie Valkenburg

• Oligo(ethylene glycol)-functionalized polycarbonate lipid nanoparticles for mRNA delivery with attenuated PEG immunogenicity - Dao TH Le
• Optimisation of a liver Trm cell-inducing mRNA vaccine by reduction of type I interferon response - Ariane Lee
• Identification and Validation of B cell epitopes within Serological Markers for Plasmodium vivax Surveillance in Malaria-endemic Regions - Hanqing Zhao
• Cost-Effectiveness of Complementary Immunisation Approaches to Protect Infants in Singapore Against Respiratory Syncytial Virus - Jingwen Zhang
• UNDERSTANDING THE ENHANCED IMMUNE RESPONSES TO HIGH-DENSITY MICROARRAY PATCH VACCINATION THROUGH SPATIAL TRANSCRIPTOMICS AND ANTIBODY REPERTOIRE ANALYSIS - Paul Young

• New Therapeutic Modalities in Infectious Diseases: Insights from Human Host‑Response and Experimental Medicine - Jenny Low
• From systems vaccinology to precision vaccinology: AI, single cell and spatial transcriptomics for predicting vaccine responses. - Helder Nakaya
• Historic 1994 Influenza Vaccine Cohorts Defines Breadth of Antibody and B Cell Responses Towards Three Decades of Future Influenza A and B Viruses - Isabelle JH Foo

• A dual anti-PD-1-BMP1 antibody-drug conjugate overcomes immunotherapy resistance - Yuval Shaked
• Subcutaneous, lymph node-directed, liposome antigen-specific immunotherapy enables immune regulation and disease suppression in autoimmune arthritis - Shehzahdi Moonshi
• Decoding Immunotherapy Resistance in Melanoma Through Tumour-Resident Immune Archetypes and Gene Regulatory Networks   - Andrea Di Pietro
• Exploiting highly immunogenic tumour cell lysate to improve the therapeutic efficacy of cancer vaccines for triple-negative breast cancer and glioblastoma - Davide Moi
• A programmable CAR T platform for viral sensing and customizable antiviral intervention - Yidan Wang
• ENGAGING HOST IMMUNITY TO DRIVE IMPROVED CONTROL OF REFRACTORY SOLID TUMORS - Paul J Neeson

• Vaccine development during and after the pandemic - Sarah Gilbert

Panellists:

• Sarah Gilbert - Oxford University
• Joe Schmitt - PrepVax
• Rosemary Tan - Leyden Labs Asia
• Anh Wartel - International Vaccine Institute